Is STRO or SVRA more profitable?

Savara has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -395.25% N/A -88.12% Savara N/A -90.28% -68.95%

Does the media prefer STRO or SVRA?

In the previous week, Sutro Biopharma had 3 more articles in the media than Savara. MarketBeat recorded 4 mentions for Sutro Biopharma and 1 mentions for Savara. Sutro Biopharma's average media sentiment score of 1.14 beat Savara's score of 1.02 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRVS or STRO?

In the previous week, Sutro Biopharma had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Sutro Biopharma and 2 mentions for Corvus Pharmaceuticals. Sutro Biopharma's average media sentiment score of 1.14 beat Corvus Pharmaceuticals' score of 0.48 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sutro Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STRO or MLTX?

In the previous week, Sutro Biopharma had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 4 mentions for Sutro Biopharma and 3 mentions for MoonLake Immunotherapeutics. Sutro Biopharma's average media sentiment score of 1.14 beat MoonLake Immunotherapeutics' score of 1.04 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STRO or JANX?

In the previous week, Sutro Biopharma had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Sutro Biopharma and 3 mentions for Janux Therapeutics. Sutro Biopharma's average media sentiment score of 1.14 beat Janux Therapeutics' score of -0.03 indicating that Sutro Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sutro Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer STRO or CVAC?

Sutro Biopharma currently has a consensus target price of $47.30, suggesting a potential upside of 189.30%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is STRO or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat CureVac's return on equity. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -395.25% N/A -88.12% CureVac 199.92% -23.03% -19.09%

Sutro Biopharma (STRO) Competitors

$16.35 +1.01 (+6.58%)

As of 09/21/2026 04:00 PM Eastern

Compare

STRO vs. SVRA, CRVS, MLTX, JANX, and CVAC

Should you buy Sutro Biopharma stock or one of its competitors? Sutro Biopharma's main competitors and comparable companies include Savara (SVRA), Corvus Pharmaceuticals (CRVS), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), and CureVac (CVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sutro Biopharma compare to Savara?

Sutro Biopharma (NASDAQ:STRO) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Sutro Biopharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Savara has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Sutro Biopharma had 3 more articles in the media than Savara. MarketBeat recorded 4 mentions for Sutro Biopharma and 1 mentions for Savara. Sutro Biopharma's average media sentiment score of 1.14 beat Savara's score of 1.02 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Savara has lower revenue, but higher earnings than Sutro Biopharma. Savara is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	2.65	-$191.09M	-$11.97	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Savara has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Savara	N/A	-90.28%	-68.95%

Sutro Biopharma presently has a consensus price target of $47.30, indicating a potential upside of 189.30%. Savara has a consensus price target of $10.00, indicating a potential upside of 83.49%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sutro Biopharma is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Sutro Biopharma beats Savara on 11 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Corvus Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Sutro Biopharma. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Sutro Biopharma	$102.48M	2.65	-$191.09M	-$11.97	N/A

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Sutro Biopharma	-395.25%	N/A	-88.12%

Corvus Pharmaceuticals presently has a consensus price target of $33.33, suggesting a potential upside of 168.38%. Sutro Biopharma has a consensus price target of $47.30, suggesting a potential upside of 189.30%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Sutro Biopharma had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Sutro Biopharma and 2 mentions for Corvus Pharmaceuticals. Sutro Biopharma's average media sentiment score of 1.14 beat Corvus Pharmaceuticals' score of 0.48 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sutro Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sutro Biopharma beats Corvus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to MoonLake Immunotherapeutics?

Sutro Biopharma (NASDAQ:STRO) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Sutro Biopharma has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	2.65	-$191.09M	-$11.97	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

Sutro Biopharma presently has a consensus target price of $47.30, suggesting a potential upside of 189.30%. MoonLake Immunotherapeutics has a consensus target price of $24.57, suggesting a potential upside of 95.79%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sutro Biopharma is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sutro Biopharma had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 4 mentions for Sutro Biopharma and 3 mentions for MoonLake Immunotherapeutics. Sutro Biopharma's average media sentiment score of 1.14 beat MoonLake Immunotherapeutics' score of 1.04 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sutro Biopharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Summary

Sutro Biopharma beats MoonLake Immunotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Janux Therapeutics?

Sutro Biopharma (NASDAQ:STRO) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Sutro Biopharma presently has a consensus price target of $47.30, suggesting a potential upside of 189.30%. Janux Therapeutics has a consensus price target of $36.46, suggesting a potential upside of 114.35%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sutro Biopharma is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Janux Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Janux Therapeutics	N/A	-11.89%	-11.13%

Janux Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Janux Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	2.65	-$191.09M	-$11.97	N/A
Janux Therapeutics	$10M	104.00	-$113.62M	-$1.64	N/A

Sutro Biopharma has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the broader market.

In the previous week, Sutro Biopharma had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Sutro Biopharma and 3 mentions for Janux Therapeutics. Sutro Biopharma's average media sentiment score of 1.14 beat Janux Therapeutics' score of -0.03 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Sutro Biopharma beats Janux Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to CureVac?

Sutro Biopharma (NASDAQ:STRO) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sutro Biopharma had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Sutro Biopharma and 0 mentions for CureVac. Sutro Biopharma's average media sentiment score of 1.14 beat CureVac's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sutro Biopharma	Positive
CureVac	Neutral

Sutro Biopharma currently has a consensus target price of $47.30, suggesting a potential upside of 189.30%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sutro Biopharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

CureVac has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	2.65	-$191.09M	-$11.97	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
CureVac	199.92%	-23.03%	-19.09%

Summary

Sutro Biopharma beats CureVac on 9 of the 17 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$254.35M	$3.90B	$7.25B	$12.97B
Dividend Yield	N/A	3.64%	2.53%	12.80%
P/E Ratio	-1.37	14.12	274.71	25.77
Price / Sales	2.65	1,420.48	696.46	109.69
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	-1.06	15.60	10.56	6.36
Net Income	-$191.09M	-$22.86M	$3.49B	$358.17M
7 Day Performance	-1.27%	0.81%	0.80%	1.60%
1 Month Performance	-22.29%	-4.59%	-2.80%	-2.97%
1 Year Performance	83.69%	34.78%	16.68%	5.63%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	3.4029 of 5 stars	$16.35 +6.6%	$47.30 +189.3%	+84.4%	$254.35M	$102.48M	N/A	128	Positive News Analyst Downgrade Gap Down
SVRA Savara	2.0858 of 5 stars	$5.34 +0.8%	$10.00 +87.3%	+54.4%	$1.09B	N/A	N/A	70	Positive News
CRVS Corvus Pharmaceuticals	2.1806 of 5 stars	$13.11 +1.5%	$33.33 +154.3%	+111.6%	$1.09B	N/A	N/A	37	Positive News
MLTX MoonLake Immunotherapeutics	2.4335 of 5 stars	$12.68 +1.4%	$24.57 +93.8%	-76.7%	$1.06B	N/A	N/A	130	Analyst Upgrade
JANX Janux Therapeutics	2.8417 of 5 stars	$17.31 +1.2%	$36.46 +110.6%	-27.5%	$1.05B	$10M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. SVRA, CRVS, MLTX, JANX, and CVAC

How does Sutro Biopharma compare to Savara?

Summary

How does Sutro Biopharma compare to Corvus Pharmaceuticals?

Summary

How does Sutro Biopharma compare to MoonLake Immunotherapeutics?

Summary

How does Sutro Biopharma compare to Janux Therapeutics?

Summary

How does Sutro Biopharma compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. SVRA, CRVS, MLTX, JANX, and CVAC

How does Sutro Biopharma compare to Savara?

Which has more volatility & risk, STRO or SVRA?

Does the media prefer STRO or SVRA?

Do institutionals & insiders believe in STRO or SVRA?

Which has stronger earnings and valuation, STRO or SVRA?

Is STRO or SVRA more profitable?

Do analysts recommend STRO or SVRA?

Summary

How does Sutro Biopharma compare to Corvus Pharmaceuticals?

Which has more volatility & risk, CRVS or STRO?

Which has higher valuation & earnings, CRVS or STRO?

Do institutionals and insiders hold more shares of CRVS or STRO?

Is CRVS or STRO more profitable?

Do analysts rate CRVS or STRO?

Does the media favor CRVS or STRO?

Summary

How does Sutro Biopharma compare to MoonLake Immunotherapeutics?

Which has higher valuation & earnings, STRO or MLTX?

Do analysts rate STRO or MLTX?

Do institutionals & insiders hold more shares of STRO or MLTX?

Does the media prefer STRO or MLTX?

Which has more volatility and risk, STRO or MLTX?

Is STRO or MLTX more profitable?

Summary

How does Sutro Biopharma compare to Janux Therapeutics?

Do analysts prefer STRO or JANX?

Is STRO or JANX more profitable?

Which has higher earnings & valuation, STRO or JANX?

Which has more volatility and risk, STRO or JANX?

Does the media refer more to STRO or JANX?

Do institutionals and insiders have more ownership in STRO or JANX?

Summary

How does Sutro Biopharma compare to CureVac?

Do insiders and institutionals have more ownership in STRO or CVAC?

Does the media prefer STRO or CVAC?

Do analysts prefer STRO or CVAC?

Which has more risk & volatility, STRO or CVAC?

Which has preferable valuation & earnings, STRO or CVAC?

Is STRO or CVAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools